The short version of Synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-06 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Immunoaffinity chromatography uses the specific binding of an antibody-antigen to selectively purify the target protein. The procedure involves immobilizing a protein to a solid substrate (e.g. a porous bead or a membrane), which then selectively binds the target, while everything else flows through. The target protein can be eluted by changing the pH or the salinity. The immobilized ligand can be an antibody (such as immunoglobulin G) or it can be a protein (such as protein A). Because this method does not involve engineering in a tag, it can be used for proteins from natural sources.
=== Research === Sherrill develops methods, algorithms, and software for quantum chemistry. He has introduced efficient density-fitting techniques into several quantum chemistry methods, speeding up computations. His research group obtains highly-accurate results for important prototype chemical systems, and uses these results to develop computational protocols that are faster yet still accurate. Sherrill focuses on intermolecular interactions, and has published definitive studies of the strength, geometric dependence, and substituent effects in prototype interactions including π-π, CH/π, S/π, and cation-π interactions. He has developed extensions of symmetry-adapted perturbation theory (SAPT) to analyze these interactions in terms of their fundamental physical forces (electrostatics, exchange/steric repulsion, induction/polarization, and London dispersion forces). A fragment-based partitioning of SAPT allows analyses of which non-bonded contacts are most important for binding, and has been used to understand substituent effects in protein-drug binding. Sherrill has published over 200 peer-reviewed articles on these topics, and presented over 130 invited lectures, including the 2011 Robert S. Mulliken Lecture at the University of Georgia, the keynote talk for the 2015 Workshop on Control of London Dispersion Interactions in Molecular Chemistry in Göttingen, and keynote talks at the 2015 and 2016 meetings of the Southeast Theoretical Chemistry Association.
=== Systemic safety and sociotechnical factors === It is common for AI risks (and technological risks more generally) to be categorized as misuse or accidents. Some scholars have suggested that this framework falls short. For example, the Cuban Missile Crisis was not clearly an accident or a misuse of technology. Policy analysts Zwetsloot and Dafoe wrote, "The misuse and accident perspectives tend to focus only on the last step in a causal chain leading up to a harm: that is, the person who misused the technology, or the system that behaved in unintended ways... Often, though, the relevant causal chain is much longer." Risks often arise from 'structural' or 'systemic' factors such as competitive pressures, diffusion of harms, fast-paced development, high levels of uncertainty, and inadequate safety culture. In the broader context of safety engineering, structural factors like 'organizational safety culture' play a central role in the popular STAMP risk analysis framework. Inspired by the structural perspective, some researchers have emphasized the importance of using machine learning to improve sociotechnical safety factors, for example, using ML for cyber defense, improving institutional decision-making, and facilitating cooperation. Others have emphasized the importance of involving both AI practitioners and domain experts in the design process to address structural vulnerabilities.
Sources: en.wikipedia.org
== Weapons and equipment == According to the United States Department of Defense, China is developing kinetic-energy weapons, high-powered lasers, high-powered microwave weapons, particle-beam weapons, and electromagnetic pulse weapons with its increase of military fundings. Responding to reports that its modernisation is dependent on sales of advanced technology from American allies, PLA senior leadership have stated: "Some have politicized China's normal commercial cooperation with foreign countries, damaging our reputation." These contributions include advanced European diesel engines for Chinese warships, military helicopter designs from Eurocopter, French anti-submarine sonars and helicopters, Australian technology for the Houbei class missile boat, and Israeli supplied American missile, laser and aircraft technology. According to the Stockholm International Peace Research Institute's data, China became the world's third largest exporter of major arms in 2010–14, an increase of 143 percent from the period 2005–2009. SIPRI also calculated that China surpassed Russia to become the world's second largest arms exporter by 2020. China's share of global arms exports hence increased from 3 to 5 percent. China supplied major arms to 35 states in 2010–14. A significant percentage (just over 68 percent) of Chinese exports went to three countries: Pakistan, Bangladesh and Myanmar. China also exported major arms to 18 African states.
Chestnuts can vary widely in shade and different terms are sometimes used to describe these shades, even though they are genetically indistinguishable. Collectively, these coat colors are usually called "red" by geneticists.
The empire's inhabitants, today generally known as Byzantines, regarded themselves as Romans (in Greek, Ῥωμαῖοι or Romaioi). Similarly, their Islamic contemporaries called their empire the "land of the Romans" (Bilād al-Rūm). After 800 AD, Western Europe called them "Greeks" (Graeci), as the Papacy and medieval German emperors regarded themselves as the true inheritors of Roman identity. The adjective "Byzantine", derived from Byzantion (Byzantium in Latin), the name of the Greek settlement Constantinople was established on, was only used to describe the inhabitants of the city; it did not refer to the empire, called Rhomanía (Ῥωμανία or "Romanland") by its citizens. Following the empire's fall, early modern scholars referred to it by many names, including the "Eastern Empire", the "Low Empire", the "Late Empire", the "Empire of the Greeks", "Empire of Constantinople", and "Roman Empire". The increasing use of "Byzantine" and "Byzantine Empire" may have started with Theodore Metochites or Laonikos Chalkokondyles whose work was widely propagated by Hieronymus Wolf. "Byzantine" was used adjectivally alongside terms such as "Empire of the Greeks" until the 19th century. It is now the primary term, used to refer to all aspects of the empire; some modern historians believe it should not be used because it was originally a prejudicial and inaccurate term.
The ancient Greek and Roman philosophers and physicians associated old age with increasing dementia. It was not until 1901 that German psychiatrist Alois Alzheimer identified the first case of what became known as Alzheimer's disease, named after him, in a fifty-year-old woman he called Auguste D. He followed her case until she died in 1906, when he first reported publicly on it. During the next five years, eleven similar cases were reported in the medical literature, some of them already using the term Alzheimer's disease. The disease was first described as a distinctive disease by Emil Kraepelin after suppressing some of the clinical (delusions and hallucinations) and pathological features (arteriosclerotic changes) contained in the original report of Auguste D. He included Alzheimer's disease, also named presenile dementia by Kraepelin, as a subtype of senile dementia in the eighth edition of his Textbook of Psychiatry, published on 15 July 1910. For most of the 20th century, the diagnosis of Alzheimer's disease was reserved for individuals between the ages of 45 and 65 who developed symptoms of dementia. The terminology changed after 1977 when a conference on Alzheimer's disease concluded that the clinical and pathological manifestations of presenile and senile dementia were almost identical, although the authors also added that this did not rule out the possibility that they had different causes. This eventually led to the diagnosis of Alzheimer's disease independent of age.
Sources: en.wikipedia.org
== Rugby league scandals == Melbourne Storm salary cap breach – in 2010, the Melbourne Storm were punished for breaching the salary cap and were stripped of the ability to accumulate points, had their name stripped from the premierships and minor premierships they had gained over the previous four years and forced to pay back millions of dollars of prize money. It is the toughest punishment for a salary cap breach in NRL history. Cronulla Sharks supplements doping scandal – following an extensive investigation by ASADA, players from the Cronulla Sharks were found guilty of having used the banned peptide CJC-1295, resulting in the suspensions of fourteen players. A number of senior staff were dismissed or resigned and several senior club members received penalties and suspensions. Matthew Johns sexual assault allegations – in 2002, while on a trip to New Zealand, Cronulla-Sutherland Sharks player Matthew Johns took part in degrading group sex with a young woman while up to 11 of his teammates joined in. The scandal was reported by the ABC's Four Corners TV series. Johns admitted having consensual sex with the girl and made a public apology on Channel Nine's The Footy Show. Johns was suspended from The Footy Show and was released by the Melbourne Storm as their assistant coach.
A haloform reaction on progesterone [57-83-0] oxidizes the 17-acetyl group into a carboxylic acid to give etienic acid [302-97-6] (2). A Schotten–Baumann reaction with tert-butylamine gives N-t-Butyl-3-oxo-4-androstene-17beta-carboxamide [131267-80-6] (3). A Lemieux–Johnson oxidation opens ring A with loss of one carbon atom. The reaction arguably involves hydroxylation of the 4–5 double bond by permanganate followed by scission of the diol by periodate. The product of the step is [190006-01-0] (4). Addition of ammonia gives a lactam-enamine [166896-74-8] (5). Catalytic hydrogenation occurs from the alpha-face [98319-24-5] (6). The reaction of the lactam with BSTFA gives an silylated imidate. Oxidation of the C1C2 position with DDQ then introduces the enone olefin group, completing the synthesis of finasteride (7).
Lacking ranging information, such systems remained of limited use in practical terms; two angle measurements could be used, but these took time to complete using existing RDF equipment and the rapid movement of the aircraft during the measurement would make coordination difficult.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.